Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zinzani, Pier Luigi, Viviani, Simonetta, Anastasia, Antonella, Vitolo, Umberto, Luminari, Stefano, Zaja, Francesco, Corradini, Paolo, Spina, Michele, Brusamolino, Ercole, Gianni, Alessandro M., Santoro, Armando, Botto, Barbara, Derenzini, Enrico, Pellegrini, Cinzia, Argnani, Lisa
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2013
Gaiak:
Original Articles and Brief Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729903/
https://ncbi.nlm.nih.gov/pubmed/23645687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083048
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak